Table 4.

Antibody response against HER2 using peptide microarray after at least three doses of the vaccine.

Patient	Response	Week 8	Week 12	Week 28	Week 48	Week 52	Week 76	Week 100
6	PD	NA	−	−	NA	NA	NA	NA
9	PR	≥2.5	≥2.5	NA	NA	−	NA	NA
11	SD	−	−	NA	NA	−	NA	NA
12	SD	NA	−	NA	NA	NA	NA	NA
14	PD	−	−	NA	NA	NA	NA	NA
16	PD	−	−	NA	NA	NA	NA	NA
17	CR	NA	NA	−	NA	≥2.5	NA	≥2.5
18	N/A (NED)	≥2.5	NA	−	−	NA	−	NA
21	SD	−	NA	−	NA	−	NA	−
25	SD	−	NA	−	NA	NA	NA	NA
26	PD	NA	−	−	NA	NA	NA	NA
27	PD	−	NA	−	NA	NA	NA	NA
29	PD	−	≥2.5	NA	NA	NA	NA	NA

The specimens were collected prior to vaccine administration on the corresponding study week. For example, week 8 sample was drawn prior to the administration of the third dose of the vaccine. Thus, the first timepoint that reflects the immune response after the third dose is week 12. Among the limited samples (n = 13) available for analysis, reactivity to HER2 peptides that was ≥2.5-fold compared with baseline was detected in three patients (patients 9, 17, and 29), among which two were the two best responders (patient 9 and patient 17). Patient 18 showed ≥2.5 but only from the sample at week 8 without sustained response. If the ratio of reactivity compared to the baseline was <2.5, it was marked as negative (–).

NA, not available.